| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 2584- | Api, | Chemo, | The versatility of apigenin: Especially as a chemopreventive agent for cancer |
| - | Review, | Var, | NA |
| 2316- | Api, | The interaction between apigenin and PKM2 restrains progression of colorectal cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | HCT8 | - | in-vivo, | CRC, | NA |
| 3391- | ART/DHA, | Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug |
| - | Review, | Var, | NA |
| 5381- | ART/DHA, | Artemisitene triggers calcium-dependent ferroptosis by disrupting the LSH-EWSR1 interaction in colorectal cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | NCM460 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT8 |
| 2570- | ART/DHA, | Discovery, mechanisms of action and combination therapy of artemisinin |
| - | Review, | Nor, | NA |
| 2572- | ART/DHA, | SRF, | Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax |
| - | in-vitro, | AML, | NA |
| 2574- | ART/DHA, | Artemisinin: A Promising Adjunct for Cancer Therapy |
| - | Review, | Var, | NA |
| 2581- | ART/DHA, | PB, | Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells |
| - | in-vitro, | AML, | NA |
| 2582- | ART/DHA, | 5-ALA, | Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
| 1142- | Ash, | Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer |
| - | Review, | BC, | MCF-7 | - | NA, | BC, | MDA-MB-231 | - | NA, | Nor, | HMEC |
| 5396- | Ash, | Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology |
| - | Review, | Var, | NA |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 3163- | Ash, | Rad, | Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis |
| 2003- | Ash, | Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | TIG-1 | - | in-vitro, | PC, | LNCaP |
| 4822- | ASTX, | Rad, | Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC) |
| 4818- | ASTX, | MEL, | Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D | - | in-vitro, | Nor, | MCF10 |
| 4810- | ASTX, | Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 4981- | ATV, | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
| 4986- | ATV, | Dipy, | The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer |
| - | Review, | Var, | NA |
| 5248- | Ba, | BA, | doxoR, | Baicalin and Baicalein Enhance Cytotoxicity, Proapoptotic Activity, and Genotoxicity of Doxorubicin and Docetaxel in MCF-7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HUVECs |
| 5250- | Ba, | Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment |
| - | Review, | Var, | NA |
| 1533- | Ba, | Baicalein, as a Prooxidant, Triggers Mitochondrial Apoptosis in MCF-7 Human Breast Cancer Cells Through Mobilization of Intracellular Copper and Reactive Oxygen Species Generation |
| - | in-vitro, | BrCC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 1523- | Ba, | Baicalein induces human osteosarcoma cell line MG-63 apoptosis via ROS-induced BNIP3 expression |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | hFOB1.19 |
| 2479- | Ba, | Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells |
| - | in-vitro, | HCC, | SW480 | - | in-vitro, | Pca, | PC3 |
| 2615- | Ba, | The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 5541- | BBM, | Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 5547- | BBM, | Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway |
| - | in-vitro, | CRC, | HT29 |
| 2023- | BBR, | Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor |
| - | in-vitro, | Colon, | NA | - | in-vitro, | Nor, | YAMC |
| 2022- | BBR, | GoldNP, | Rad, | Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition |
| - | in-vitro, | Liver, | SMMC-7721 cell | - | in-vitro, | Nor, | HL7702 |
| 2021- | BBR, | Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways |
| - | Review, | NA, | NA |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2707- | BBR, | Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| 5178- | BBR, | Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 5582- | BetA, | Targeting mitochondrial apoptosis by betulinic acid in human cancers |
| - | Review, | Var, | NA |
| 5591- | BetA, | Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment |
| - | Review, | BC, | NA |
| 5587- | BetA, | Rad, | Effects of betulinic acid alone and in combination with irradiation in human melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 5583- | BetA, | Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells |
| - | vitro+vivo, | NA, | NA |
| 943- | BetA, | Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2718- | BetA, | The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis |
| - | in-vitro, | AML, | U937 |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2732- | BetA, | Chemo, | Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 2735- | BetA, | Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications |
| - | Review, | Var, | NA |
| 2747- | BetA, | Betulinic acid, a natural compound with potent anticancer effects |
| - | Review, | Var, | NA |
| 2752- | BetA, | Betulinic acid: a natural product with anticancer activity |
| - | Review, | Var, | NA |
| 5715- | BF, | Bufalin for an innovative therapeutic approach against cancer |
| - | Review, | Var, | NA |
| 5628- | Bif, | immuno, | Bifidobacterium modulation of tumor immunotherapy and its mechanism |
| - | Review, | Var, | NA |
| 5629- | Bif, | ProBio, | Gut microbiota shapes cancer immunotherapy responses |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid